CD4+ T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro
暂无分享,去创建一个
H. Petrie | M. Brady | David D. Eckels | Janet S. Lee | D. Eckels | Mary S. Brady | Fei Lee | H. Petrie | F. Lee
[1] S. Ferrone,et al. DR (Ia-like) antigens on human melanoma cells. Serological detection and immunochemical characterization , 1979, The Journal of experimental medicine.
[2] B. Dörken,et al. Induction of HLA class‐II antigen expression on human carcinoma cell lines by IFN‐gamma , 1985, International journal of cancer.
[3] J. Becker,et al. Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. , 1993, International immunology.
[4] B. Dréno,et al. HLA class II‐restricted recognition of common tumor epitopes on human melanoma cells by CD4+ melanoma‐infiltrating lymphocytes , 1995, European journal of immunology.
[5] E. Bröcker,et al. HLA-DR antigen expression in primary melanomas of the skin. , 1984, The Journal of investigative dermatology.
[6] S. Rosenberg,et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[7] B. Giannotti,et al. Ki67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions. , 1990, The Journal of investigative dermatology.
[8] R. Locksley,et al. Altered Immune Responses in Interleukin 10 Transgenic Mice , 1997, The Journal of experimental medicine.
[9] D. Pardoll,et al. The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.
[10] J. McCluskey,et al. Class II-restricted presentation of an endogenously derived immunodominant T-cell determinant of hen egg lysozyme. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[11] S. Kimura,et al. CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. , 1998, Cancer research.
[12] C. Y. Wang,et al. Expression of Ia-like antigens on cultured human malignant melanoma cell lines. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[13] A. Billiau,et al. Immunomodulatory Properties of Interferon‐γ: An Update a , 1998 .
[14] D. Ruiter,et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. , 1988, Cancer research.
[15] J. D. de Vries,et al. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells , 1996, The Journal of experimental medicine.
[16] J. Kirkwood,et al. Immune response to autologous human melanoma: implication of class I and II MHC products. , 1986, Biochimica et biophysica acta.
[17] William Arbuthnot Sir Lane,et al. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles , 1993, The Journal of experimental medicine.
[18] D. Ruiter,et al. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. , 1984, Cancer Research.
[19] Eric O Long,et al. Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells , 1992, Nature.
[20] J S Lee,et al. MHC class II-mediated antigen presentation by melanoma cells. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[21] P. Marrack,et al. Interleukin-induced increase in Ia expression by normal mouse B cells , 1984, The Journal of experimental medicine.
[22] J. Ting,et al. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[23] J. Woody,et al. Human T-cell clones recognize chemically synthesized peptides of influenza haemagglutinin , 1982, Nature.
[24] A. Rejthar,et al. DNA content and MHC class II antigen expression in malignant melanoma: clinical course. , 1988, Journal of clinical pathology.
[25] L. Lampson,et al. Two populations of Ia-like molecules on a human B cell line. , 1980, Journal of immunology.
[26] S. Ostrand-Rosenberg,et al. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. , 1998, Journal of immunology.
[27] A. Houghton,et al. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity. , 1990, Cancer research.
[28] F. Brodsky,et al. Class II molecules of the major histocompatibility complex considered as differentiation markers. , 1986, Human immunology.
[29] J. Uhr,et al. Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[30] D. Ruiter,et al. Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma. , 1988, The Journal of investigative dermatology.
[31] R. Klausner,et al. Class II MHC molecules can use the endogenous pathway of antigen presentation , 1990, Nature.
[32] A. Billiau,et al. Immunomodulatory properties of interferon-gamma. An update. , 1998, Annals of the New York Academy of Sciences.